In patients with NASH, nonbile acid–derived FXR agonists EDP-305 and tropifexor (which is also a nonsteroidal FXR agonist) were also associated with pruritus as the most commonly reported adverse event, suggesting that this is a class effect [48,49]. The gene discussed is NR1H4; the disease is Pruritus.